

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/802,472
Filing Date	March 9, 2001
First Named Inventor	Paz EINAT
Confirmation No.	7736
Examiner Name	Y. Kim
Attorney Docket Number	EINAT=4.1C

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

RECEIVED**DEC 16 2002****TECH CENTER 1600/2900****FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
<i>JK</i>	BC	WO	96/39426	A1	Johns Hopkins Univ Sch Med	12-12-1996		
<i>JK</i>	BD	WO	98/39448	A2	Human Genome Sciences, Inc.	09-11-1998		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>JK</i>	BE	BAE et al, "Identification of Genes Differentially Expressed by Hypoxia in Hepatocellular Carcinoma Cells", <u>Biochem Biophys Res Comm</u> 243(1):158-162	
<i>JK</i>	BF	BLANCHER et al, "The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target", <u>Cancer Metastasis Rev</u> 17(2):187-194 (1998)	

Examiner
Signature*[Signature]*Date
Considered*2-4-03*

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 3

Complete if Known

Application Number	09/802,472
Filing Date	March 9, 2001
First Named Inventor	Paz EINAT
Confirmation No.	7736
Examiner Name	
Attorney Docket Number	EINAT=4.1C

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	Adams et al, "Complementary DNA sequencing: expressed sequence tags and human genome project", <u>Science</u> 252(5013):1651-1656 (1991)	
	AB	An et al, "Stabilization of wild-type p53 by Hypoxia-Inducible Factor-1 α ", <u>Nature</u> 392:405-408 (1998)	
	AC	Barone et al, "CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest", <u>Genes Dev</u> 8(4):453-464 (1994)	
	AD	Baudet et al, "1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line", <u>J Neurosci Res</u> 46(5):540-550 (1996)	
	AE	Blagosklonny et al, "p53 inhibits Hypoxia-Inducible Factor-Stimulated Transcription", <u>J Biol Chem</u> 273:11995-11998 (1998)	
	AF	Bunn et al, "Oxygen sensing and molecular adaptation in hypoxia", <u>Physiol Rev</u> 76:839-885 (1996)	
	AG	Carmeliet et al, "Role of HIF-1 α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis", <u>Nature</u> 394(6692):485-490 (1998, July 30)	
	AH	Chen et al, "Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis", <u>Oncogene</u> 13(8):1659-1665 (1996)	
	AI	Clark et al, "Apoptosis-suppressor gene bcl-2 expression after traumatic brain injury in rats", <u>J. Neurosci</u> 17:9172-9182 (1997)	
	AJ	Dor et al, "Ischemia-driven angiogenesis", <u>Trends Cardiovasc Med</u> 7:289-294 (1997)	
	AK	Fleming et al, "The effects of nutrient deprivation and differentiation on the expression of growth arrest genes (gas and gadd) in F9 embryonal carcinoma cells", 330:573-579 (1998)	
	AL	Forance et al, "Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents", <u>Mol Cell Biol</u> 9:4196-4203 (1989)	

Examiner
SignatureDate
Considered

Feb 4, 03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/802,472
		Filing Date	March 9, 2001
		First Named Inventor	Paz EINAT
		Confirmation No.	7736
		Examiner Name	
Sheet 2	of 3	Attorney Docket Number	EINAT=4.1C



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AM	Graeber et al, "Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours", <u>Nature</u> 379(6560):88-91 (1996)	
	AN	Hampton et al, "Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis", <u>FEBS Lett</u> 414:552-556 (1997)	
	AO	Hanahan et al, "Patterns and Emerging Mechanisms of Angiogenic Switch During Tumorigenesis", <u>Cell</u> 86:353-364 (1996)	
	AP	Hockenbery et al, "Bcl-2 functions in an antioxidant pathway to prevent apoptosis", <u>Cell</u> 75:241-251 (1993)	
	AQ	Hollander et al, "Analysis of the mammalian gadd45 gene and its response to DNA damage", <u>J Biol Chem</u> 268(32):24385-24393 (1993)	
	AR	Kondo et al, "Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells", <u>Oncogene</u> 17:2585-2591 (1998)	
	AS	Nicholson et al, "Caspases: killer proteases", <u>Trends Biochem Sci</u> 22:299-306 (1997)	
	AT	Reed JC, "Bcl-2 and the regulation of programmed cell death", <u>J Cell Biol</u> 124:1-6 (1994)	
	AU	Schena et al, "Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes", <u>Proc Natl Acad Sci USA</u> 93(20):10614-10619 (1996)	
	AV	Schmidt-Kastner et al, "Pixel-based image analysis of HSP70, GADD45 and MAP2 mRNA expression after focal cerebral ischemia: hemodynamic and histological correlates", <u>Brain Res Mol Brain Res</u> 63:79-97 (1998)	
	AW	Shibata et al, "Caspases determine the vulnerability of oligodendrocytes in the ischemic brain", <u>J Clin Invest</u> 106:643-653 (2000)	
	AX	Takekawa et al, "A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK", <u>Cell</u> 95:521-530 (1998)	

Examiner Signature		Date Considered	2-4-03
--------------------	--	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Application Number	09/802,472
Filing Date	March 9, 2001
First Named Inventor	Paz EINAT
Confirmation No.	7736
Examiner Name	
Attorney Docket Number	EINAT=4.1C

[illegible]

Examiner
Signature

Date
Considered

2-24-03

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.